Loading…
IRADIMED CORPORATION is projected to rise to $122.89 by 2027, a +35% move from its current price of $90.86. IRMD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $89.26 | $90.93 | $92.62 | +0.07% |
| Aug 3 | $88.65 | $90.99 | $93.40 | +0.14% |
| Aug 4 | $88.19 | $91.06 | $94.01 | +0.22% |
| Aug 5 | $87.82 | $91.12 | $94.55 | +0.29% |
| Aug 6 | $87.50 | $91.19 | $95.03 | +0.36% |
| Aug 7 | $87.22 | $91.25 | $95.47 | +0.43% |
| Aug 8 | $86.97 | $91.32 | $95.89 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $86.97 | $91.32 | $95.89 | +0.51% |
| Week 2 | $85.66 | $91.78 | $98.34 | +1.01% |
| Week 3 | $84.77 | $92.25 | $100.38 | +1.52% |
| Week 4 | $84.09 | $92.71 | $102.22 | +2.04% |
| Week 5 | $83.55 | $93.18 | $103.92 | +2.55% |
| Week 6 | $83.10 | $93.65 | $105.54 | +3.07% |
| Week 7 | $82.73 | $94.13 | $107.10 | +3.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IRADIMED CORPORATION develops, manufactures, markets, and distributes MRI-compatible intravenous infusion pump systems and MRI-compatible patient vital signs monitoring systems and related accessories. It offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers and sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
IRMD is currently priced at $93.62 and has a market cap of $1.2B. It ranks 2430 by market capitalization.
The near-term price outlook reflects a 30-day range of $83.44 to $128.81, with an average of $93.62 and a neutral sentiment.
Looking further ahead, the forecast shows a rising price path with the 2030 average at $185.68 and the 2050 average at $870.24, while the 2030 max reaches $254.50 and the 2050 max reaches $1,438.64. The sentiment moves to bullish in later years, suggesting meaningful upside potential over the long term.
A major floor 8.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 12.6% above — a clean break opens room to run.
A major ceiling 16.8% above — clearing it would confirm fresh momentum.
Key IRMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IRMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $94.05 | Sell | $93.51 | Sell |
| MA 10 | $94.47 | Sell | $94.29 | Sell |
| MA 20 | $95.83 | Sell | $94.81 | Sell |
| MA 50 | $94.35 | Sell | $94.33 | Sell |
| MA 100 | $93.54 | Sell | $93.62 | Sell |
| MA 200 | $93.49 | Sell | $89.63 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.07 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -156.44 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.52 | Sell |
| ROC (12) | -2.95 | Sell |
| Bollinger %B (20,2) | 0.03 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.04 | Buy |
| Awesome (5,34) | -0.99 | Sell |
| Ultimate (7,14,28) | 33.52 | Neutral |
| Momentum (10) | -6.17 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 93.69 | Sell |
| ADX (14) | 9.89 | Neutral |
| ATR (14) | 1.52 | Info |
The 30-day technical picture is labeled as BULLISH, with RSI(14) at 50.
The 50-day simple moving average sits at $92.23 and the 200-day simple moving average sits at $92.13, indicating a narrow moving-average backdrop.
Key support is listed at $89.86 and resistance at $102.30. The 30-day price range is $82.29 to $106.51, and the annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $83.44 | $90.86 | $121.28 | 0% | Neutral | |
| $100.77 | $122.89 | $156.61 | +35% | Bullish | |
| $118.05 | $146.71 | $192.10 | +61% | Bullish | |
| $123.93 | $156.42 | $209.22 | +72% | Bullish | |
| $138.59 | $177.29 | $241.45 | +95% | Bullish | |
| $142.94 | $185.11 | $256.10 | +104% | Bullish | |
| $145.58 | $190.67 | $267.57 | +110% | Bullish | |
| $183.70 | $243.13 | $345.62 | +168% | Bullish | |
| $206.67 | $276.26 | $397.44 | +204% | Bullish | |
| $213.72 | $288.40 | $419.53 | +217% | Bullish | |
| $309.27 | $435.31 | $663.71 | +379% | Bullish | |
| $523.72 | $790.65 | $1,292.35 | +770% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $83.44 | $90.86 | $106.94 | +0.00% |
| September 2026 | $79.57 | $93.29 | $111.87 | +2.68% |
| October 2026 | $82.38 | $97.03 | $117.22 | +4.01% |
| November 2026 | $82.46 | $97.50 | $118.50 | +0.48% |
| December 2026 | $83.64 | $99.24 | $121.28 | +1.79% |
Click any year to see its month-by-month IRMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
IRADIMED CORPORATION's 2026 outlook centres on $90.86, within a $83.44 to $121.28 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, IRMD could reach as high as $156.61, with a base case around $122.89 and support toward $100.77 — roughly +35% from $90.86. Momentum favours further upside here.
Expect IRMD to range from $118.05 to $192.10 through 2028. The $146.71 average target implies a +61% move from current prices. That is up +19% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The IRMD price prediction for 2029 points to an average of $156.42 (low $123.93, high $209.22) — a potential gain of +72% on today's $90.86. Momentum favours further upside here.
In 2030, IRMD is projected to trade between $138.59 and $241.45, averaging $177.29 — a potential gain of +95% from today's $90.86. That is up +13% on the projected 2029 average. Buyers look set to stay in control over this stretch.
IRADIMED CORPORATION's 2031 outlook centres on $185.11, within a $142.94 to $256.10 range. That is up +4% on the projected 2030 average. That marks a +104% change versus current levels. Momentum favours further upside here.
By 2032, IRMD could reach as high as $267.57, with a base case around $190.67 and support toward $145.58 — roughly +110% from $90.86. Buyers look set to stay in control over this stretch.
Expect IRMD to range from $183.70 to $345.62 through 2033. The $243.13 average target implies a +168% move from current prices. That is up +28% on the projected 2032 average. Momentum favours further upside here.
The IRMD price prediction for 2034 points to an average of $276.26 (low $206.67, high $397.44) — a potential gain of +204% on today's $90.86. Buyers look set to stay in control over this stretch.
In 2035, IRMD is projected to trade between $213.72 and $419.53, averaging $288.40 — a potential gain of +217% from today's $90.86. That is up +4% on the projected 2034 average. Momentum favours further upside here.
IRADIMED CORPORATION's 2040 outlook centres on $435.31, within a $309.27 to $663.71 range. That is up +51% on the projected 2035 average. That marks a +379% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, IRMD could reach as high as $1,292.35, with a base case around $790.65 and support toward $523.72 — roughly +770% from $90.86. Momentum favours further upside here.
Investing $1,000 in IRMD today (≈ 11.005943 IRMD) could be worth
$8,701.83
+$7,701.83 (+770%) by 2050 · US Dollar
Based on the average projected IRMD price of $790.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IRMDwould be worth at today's price.
$1,000 invested in IRMD on Jul 31, 2025 (≈ 17.140898 IRMD) would be worth
$1,557.42
+$557.42 (+55.7%) today · 1.56× · US Dollar
Based on a IRMD entry price of $58.34 vs. today's $90.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $94.49 | $961.58 | -3.8% |
| 1 month ago | $98.04 | $926.76 | -7.3% |
| 3 months ago | $87.15 | $1,042.57 | +4.3% |
| 6 months ago | $99 | $917.78 | -8.2% |
| 1 year ago | $58.34 | $1,557.42 | +55.7% |
| All time (5.0y) ago | $34.81 | $2,610.17 | +161.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IRMD forecast.
Our base-case forecast reaches $180.00 around 2031.
Implied market cap at $180.00: $2.3B
The multi-year forecast foresees substantial appreciation, with the 2026 average at $93.62 and a bullish trajectory continuing through 2030 at $185.68 average and 98.3% ROI.
From 2027 onward, the outlook strengthens, with the 2027 average at $128.09 and ROI of 36.8%, 2028 at $152.37 (62.8%), 2029 at $167.05 (78.4%), and 2030 at $185.68 (98.3%) as the pace accelerates toward a bullish long-run path. By 2040, the average forecast reaches $464.67 with a 396.3% ROI, and by 2050 the average is $870.24 with an 829.5% ROI.
The maximums also illustrate strong upside, with $254.50 in 2030 and $1,438.64 in 2050, while the sentiment remains bullish across the extended horizon. These are estimates and not guarantees; actual results may differ due to market and company-specific factors.
Tap a question to reveal the answer.
2030 avg $185.68, min $144.43, max $254.50; ROI 98.3%; sentiment BULLISH.
Forecasts show bullish sentiment in 2027 and beyond with rising averages and strong long-run ROI (36.8% in 2027; 829.5% by 2050); 2026 is neutral.
Yes. The forecast shows 2032 avg $205.42, 2033 avg $260.26 with a max of $372.80, indicating potential for surpassing $200 in the early 2030s.
2026 min $83.44, avg $93.62, max $128.81; sentiment NEUTRAL.
2050 avg $870.24, max $1,438.64; ROI 829.5%; sentiment BULLISH.
IRADIMED CORPORATION Community Discussion
0Share your IRADIMED CORPORATION price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.